Related Experiment Video
Updated: Sep 26, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol
Marvin Rubenstein1, Leonid Slobodskoy, Yelena Mirochnik
1Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, IL, USA. DrMarv@Prodigy.net
Abstract:
Antisense oligonucleotides (oligos) directed against mRNA-encoding transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR) have demonstrated in vitro and in vivo efficacy against prostate cancer tumor models. However, many therapeutic agents have increased effectiveness when given in combination with other more established agents. We evaluated the effectiveness of two oligos (3.32 and 6.64 microM/L) known to have significant activity against the PC-3 prostate cell line in combination therapy with the chemotherapeutic agent paclitaxel (Taxol) (2.5 and 5.0 nm). Therapy was evaluated when oligos and Taxol were administered either as (1) single agents, (2) simultaneously in a combined therapy, or (3) sequentially, a form of combination therapy with both agents being administered in a series. We found that when either of the two oligos were given simultaneously with Taxol, no synergistic activity was noted. However, when sequentially administered in a series 1 d apart, a pretreatment with the antisense directed against TGF-alpha (6.64 microM/L) followed by Taxol (5 nm) had significantly greater activity than these agents similarly administered in the reverse order or simultaneously.>
Insights
Combining antisense oligonucleotides (oligos) targeting TGF-alpha with paclitaxel showed enhanced prostate cancer treatment efficacy. Sequential administration, with TGF-alpha oligos preceding paclitaxel, proved most effective, outperforming simultaneous or reversed sequential treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Antisense oligonucleotides (oligos) targeting transforming growth factor-alpha (TGF-alpha) and epidermal growth factor receptor (EGFR) show promise in preclinical prostate cancer models.
- Combination therapy is a strategy to enhance the effectiveness of established chemotherapeutic agents.
Purpose of the Study:
- To evaluate the combination therapy of TGF-alpha and EGFR targeting antisense oligos with paclitaxel (Taxol) in prostate cancer.
- To determine the optimal administration schedule (simultaneous vs. sequential) for this combination therapy.
Main Methods:
- Two antisense oligos with known activity against the PC-3 prostate cell line were tested.
- Oligos were combined with paclitaxel at various concentrations (3.32-6.64 microM/L for oligos, 2.5-5.0 nm for paclitaxel).
- Therapeutic efficacy was assessed for single-agent, simultaneous combination, and sequential (1 day apart) administration.
Main Results:
- Simultaneous administration of oligos and paclitaxel did not yield synergistic effects.
- Sequential administration showed significantly greater activity compared to simultaneous treatment.
- Pretreatment with TGF-alpha antisense oligo (6.64 microM/L) followed by paclitaxel (5 nm) demonstrated superior efficacy over reverse sequential or simultaneous administration.
Conclusions:
- Sequential administration of antisense oligos and paclitaxel can enhance therapeutic outcomes in prostate cancer.
- A specific sequential regimen (TGF-alpha oligo followed by paclitaxel) shows significant promise for combination therapy.
- Further investigation into sequential antisense oligo and chemotherapy combinations is warranted for prostate cancer treatment.
